英文字典中文字典


英文字典中文字典51ZiDian.com



中文字典辞典   英文字典 a   b   c   d   e   f   g   h   i   j   k   l   m   n   o   p   q   r   s   t   u   v   w   x   y   z       







请输入英文单字，中文词皆可：


请选择你想看的字典辞典：
单词字典翻译
Subsisted查看　Subsisted　在百度字典中的解释百度英翻中〔查看〕
Subsisted查看　Subsisted　在Google字典中的解释Google英翻中〔查看〕
Subsisted查看　Subsisted　在Yahoo字典中的解释Yahoo英翻中〔查看〕

安装中文字典英文字典查询工具!


中文字典英文字典工具:
选择颜色:
输入中英文单字

































































英文字典中文字典相关资料:


  • Treatment in Advanced NSCLC | LIBTAYO® (cemiplimab-rwlc)
    or your lung cancer has spread to other areas of your body (metastatic lung cancer), and your tumor does not have an abnormal “EGFR,” “ALK,” or “ROS1” gene LIBTAYO may be used as your first treatment: In combination with chemotherapy that contains a platinum medicine, or alone if your tumor tests positive for high “PD-L1 ”
  • LIBTAYO works with your immune system to help treat advanced . . .
    LIBTAYO may be used as your first treatment when your lung cancer has not spread outside your chest (locally advanced lung cancer) and you cannot have surgery or chemotherapy with radiation, or your lung cancer has spread to other areas of your body (metastatic lung cancer), and your tumor tests positive for high “PD-L1,” and your tumor
  • How Libtayo Works for Non-Small-Cell Lung Cancer - WebMD
    Libtayo may also be used along with a platinum-based chemotherapy as an initial (first-line) treatment for advanced or metastatic NSCLC that does not have other targetable mutations of EGFR, ALK
  • Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell . . .
    First-line therapy for advanced non–small-cell lung cancer (NSCLC) that lacks targetable mutations is platinum-based chemotherapy Among patients with a tumor proportion score for programmed
  • LIBTAYO® (cemiplimab-rwlc) in Advanced NSCLC
    LIBTAYO in combination with platinum-based chemotherapy is indicated for the first-line treatment of adult patients with non–small cell lung cancer (NSCLC) with no EGFR, ALK, or ROS1 aberrations, and is locally advanced where patients are not candidates for surgical resection or definitive chemoradiation OR metastatic 1 Review combination therapy data
  • Treatment of metastatic ALK-positive non-small cell lung . . .
    Clinical and demographic characteristics of patients with advanced ALK-positive non-small cell lung cancer treated at Karolinska University Hospital between January 2009 and December 2021
  • Libtayo® (cemiplimab) Plus Chemotherapy Results . . . - BioSpace
    The five-year results for Libtayo plus chemotherapy presented at WCLC add to the breadth of long-term data for Libtayo in advanced NSCLC, including five-year outcomes from the EMPOWER-Lung 1 trial that were presented at WCLC 2024 confirming durable survival benefit as monotherapy
  • Libtayo® (cemiplimab-rwlc) Approved in the U. S. as First and . . .
    LIBTAYO may be used alone as your first treatment when your lung cancer has not spread outside your chest (locally advanced lung cancer) and you cannot have surgery or chemotherapy with radiation
  • Metastatic Non-Small Cell Lung Cancer - NCCN
    Non-small cell lung cancer (NSCLC) is the most common type of lung cancer Treatment combined with supportive care have improved the lives of people with NSCLC
  • What is LIBTAYO® (cemiplimab-rwlc) | Advanced NSCLC
    LIBTAYO (Lib-TIE-oh) is a prescription medicine used to treat adults with a type of lung cancer called non–small cell lung cancer (NSCLC) LIBTAYO may be right for adults with advanced NSCLC who have tumors that do not have an abnormal “EGFR,” “ALK,” or “ROS1” gene, and whose NSCLC: And LIBTAYO may be used as your first treatment alone if your tumor tests positive for high “PD





中文字典-英文字典  2005-2009